FGP
BBNX icon

Freestone Grove Partners’s Beta Bionics BBNX Stock Holding History

Freestone Grove Partners’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63 Buy
+4
New +$48 ﹤0.01% 937
2026
Q1 		– Sell
-138,138
Closed -$4.21M – 1213
2025
Q4 		$4.21M Buy
+138,138
New +$3.69M 0.03% 361

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Freestone Grove Partners's BBNX Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Beta Bionics (BBNX) in Q2 2026: 4 shares worth $63. The stake represents ﹤0.01% of the portfolio and ranks #937 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in BBNX as recently as Q4 2025.

Freestone Grove Partners first reported a position in BBNX in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.21M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Freestone Grove Partners held 4 shares of Beta Bionics worth $63 as of Q2 2026.
  • Beta Bionics was a new Freestone Grove Partners position in Q2 2026.
  • Beta Bionics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #937 holding.
  • Freestone Grove Partners first reported a position in Beta Bionics in Q4 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Beta Bionics position peaked at $4.21M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.